CoChat

Reclassifying Hepatic Cell Death during Liver Damage: Ferroptosis—A Novel Form of Non-Apoptotic Cell Death?

Open access
Macías-Rodríguez, Ricardo U., Inzaugarat, María Eugenia, Ruiz-Margáin, Astrid, Nelson, Leonard J., Trautwein, Christian, Cubero, Francisco Javier · 2020 · International Journal of Molecular Sciences
Cited by 115

The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.

Abstract

Ferroptosis has emerged as a new type of cell death in different pathological conditions, including neurological and kidney diseases and, especially, in different types of cancer. The hallmark of this regulated cell death is the presence of iron-driven lipid peroxidation; the activation of key genes related to this process such as glutathione peroxidase-4 (gpx4), acyl-CoA synthetase long-chain family member-4 (acsl4), carbonyl reductase [NADPH] 3 (cbr3), and prostaglandin peroxidase synthase-2 (ptgs2); and morphological changes including shrunken and electron-dense mitochondria. Iron overload in the liver has long been recognized as both a major trigger of liver damage in different diseases, and it is also associated with liver fibrosis. New evidence suggests that ferroptosis might be a novel type of non-apoptotic cell death in several liver diseases including non-alcoholic steatohepatitis (NASH), alcoholic liver disease (ALD), drug-induced liver injury (DILI), viral hepatitis, and hemochromatosis. The interaction between iron-related lipid peroxidation, cellular stress signals, and antioxidant systems plays a pivotal role in the development of this novel type of cell death. In addition, integrated responses from lipidic mediators together with free iron from iron-containing enzymes are essential to understanding this process. The presence of ferroptosis and the exact mechanisms leading to this non-apoptotic type of cell death in the liver remain scarcely elucidated. Recognizing ferroptosis as a novel type of cell death in the liver could lead to the understanding of the complex interaction between different types of cell death, their role in progression of liver fibrosis, the development of new biomarkers, as well as the use of modulators of ferroptosis, allowing improved theranostic approaches in the clinic.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/ijms21051651

Cites

54 of 54 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 54 references

Research works printed but not linked: 134

  1. Green, 2002, AGA technical review on the evaluation of liver chemistry tests, Gastroenterology, 123, 1367, 10.1053/gast.2002.36061 · DOI · Paper page
  2. Rinella, 2015, Nonalcoholic fatty liver disease: A systematic review, JAMA, 313, 2263, 10.1001/jama.2015.5370 · DOI · Paper page
  3. Moriyama, 2005, Decreased risk of hepatocellular carcinoma in patients with chronic hepatitis C whose serum alanine aminotransferase levels became less than twice the upper limit of normal following interferon therapy, Liver Int., 25, 85, 10.1111/j.1478-3231.2005.01028.x · doi:10.1111/j.1478-3231.2005.01028.x
  4. Miyake, 2006, Persistent elevation of serum alanine aminotransferase levels leads to poor survival and hepatocellular carcinoma development in type 1 autoimmune hepatitis, Aliment. Pharmacol. Ther., 24, 1197, 10.1111/j.1365-2036.2006.03113.x · DOI
  5. Eguchi, 2014, Biomarkers of liver cell death, J. Hepatol., 60, 1063, 10.1016/j.jhep.2013.12.026 · DOI · Paper page
  6. Luedde, 2014, Cell death and cell death responses in liver disease: Mechanisms and clinical relevance, Gastroenterology, 147, 765, 10.1053/j.gastro.2014.07.018 · DOI · Paper page
  7. Wang, 2015, Molecular mechanisms of hepatic apoptosis regulated by nuclear factors, Cell. Signal., 27, 729, 10.1016/j.cellsig.2014.11.038 · DOI
  8. Dixon, 2012, Ferroptosis: An iron-dependent form of nonapoptotic cell death, Cell, 149, 1060, 10.1016/j.cell.2012.03.042 · DOI · Paper page
  9. Mehta, 2019, Iron and liver fibrosis: Mechanistic and clinical aspects, World J. Gastroenterol., 25, 521, 10.3748/wjg.v25.i5.521 · DOI · Paper page
  10. Pietrangelo, 2009, Iron in NASH, chronic liver diseases and HCC: How much iron is too much?, J. Hepatol., 50, 249, 10.1016/j.jhep.2008.11.011 · DOI
  11. Li, 2015, The Role of Oxidative Stress and Antioxidants in Liver Diseases, Int. J. Mol. Sci., 16, 26087, 10.3390/ijms161125942 · DOI · Paper page
  12. Man, 2016, Converging roles of caspases in inflammasome activation, cell death and innate immunity, Nat. Rev. Immunol., 16, 7, 10.1038/nri.2015.7 · DOI · Paper page
  13. Hotchkiss, 2009, Cell Death, N. Engl. J. Med., 361, 1570, 10.1056/NEJMra0901217 · DOI · Paper page
  14. Rautou, 2008, Acute Liver Cell Damage in Patients With Anorexia Nervosa: A Possible Role of Starvation-Induced Hepatocyte Autophagy, Gastroenterology, 135, 840, 10.1053/j.gastro.2008.05.055 · DOI · Paper page
  15. Lamkanfi, 2016, Pyroptosis, Curr. Biol., 26, R568, 10.1016/j.cub.2016.02.019 · DOI · Paper page
  16. Wallach, 2016, Programmed necrosis in inflammation: Toward identification of the effector molecules, Science, 352, aaf2154, 10.1126/science.aaf2154 · DOI · Paper page
  17. Mizushima, 2011, Autophagy: Renovation of cells and tissues, Cell, 147, 728, 10.1016/j.cell.2011.10.026 · DOI · Paper page
  18. Cadwell, 2016, Crosstalk between autophagy and inflammatory signalling pathways: Balancing defence and homeostasis, Nat. Rev. Immunol., 16, 661, 10.1038/nri.2016.100 · DOI · Paper page
  19. Denton, 2019, Autophagy-dependent cell death, Cell Death Differ., 26, 605, 10.1038/s41418-018-0252-y · DOI · Paper page
  20. Guicciardi, 2005, Apoptosis: A mechanism of acute and chronic liver injury, Gut, 54, 1024, 10.1136/gut.2004.053850 · DOI · Paper page
  21. Wang, 2014, Molecular mechanisms of hepatic apoptosis, Cell Death Dis., 5, e996, 10.1038/cddis.2013.499 · DOI · Paper page
  22. Taylor, 2008, Apoptosis: Controlled demolition at the cellular level, Nat. Rev. Mol. Cell Biol., 9, 231, 10.1038/nrm2312 · DOI · Paper page
  23. Canbay, 2003, Kupffer cell engulfment of apoptotic bodies stimulates death ligand and cytokine expression, Hepatology, 38, 1188, 10.1053/jhep.2003.50472 · DOI · Paper page
  24. Green, 1998, Mitochondria and apoptosis, Science, 281, 1309, 10.1126/science.281.5381.1309 · DOI · Paper page
  25. Bao, 2007, Apoptosome: A platform for the activation of initiator caspases, Cell Death Differ., 14, 56, 10.1038/sj.cdd.4402028 · DOI · Paper page
  26. Ow, 2008, Cytochrome c: Functions beyond respiration, Nat. Rev. Mol. Cell Biol., 9, 532, 10.1038/nrm2434 · DOI · Paper page
  27. Wilson, 2009, Death receptor signal transducers: Nodes of coordination in immune signaling networks, Nat. Immunol., 10, 348, 10.1038/ni.1714 · DOI · Paper page
  28. Bordon, 2016, Cell death and immunity: Gasdermins: The hole picture emerges, Nat. Rev. Immunol., 16, 401, 10.1038/nri.2016.76 · doi:10.1038/nri.2016.76
  29. Thome, 1997, Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors, Nature, 386, 517, 10.1038/386517a0 · DOI · Paper page
  30. Galluzzi, 2017, Necroptosis: Mechanisms and Relevance to Disease, Annu. Rev. Pathol. Mech. Dis., 12, 103, 10.1146/annurev-pathol-052016-100247 · DOI · Paper page
  31. Krysko, 2008, Apoptosis and necrosis: Detection, discrimination and phagocytosis, Methods, 44, 205, 10.1016/j.ymeth.2007.12.001 · DOI · Paper page
  32. Tomaipitinca, L., Mandatori, S., Mancinelli, R., Giulitti, F., Petrungaro, S., Moresi, V., Facchiano, A., Ziparo, E., Gaudio, E., and Giampietri, C. (2019). The Role of Autophagy in Liver Epithelial Cells and Its Impact on Systemic Homeostasis. Nutrients, 11. · DOI
  33. Mizushima, 2008, Autophagy fights disease through cellular self-digestion, Nature, 451, 1069, 10.1038/nature06639 · DOI · Paper page
  34. Yang, 2007, Permeases recycle amino acids resulting from autophagy, Autophagy, 3, 149, 10.4161/auto.3631 · DOI
  35. Fleming, 2012, Iron overload in human disease, N. Engl. J. Med., 366, 348, 10.1056/NEJMra1004967 · DOI · Paper page
  36. Meynard, 2014, The liver: Conductor of systemic iron balance, Blood, 123, 168, 10.1182/blood-2013-06-427757 · DOI · Paper page
  37. Zhao, 2013, Iron regulation by hepcidin, J. Clin. Invest., 123, 2337, 10.1172/JCI67225 · DOI · Paper page
  38. Gaschler, 2017, Lipid peroxidation in cell death, Biochem. Biophys. Res. Commun., 482, 419, 10.1016/j.bbrc.2016.10.086 · DOI · Paper page
  39. Feng, H., and Stockwell, B.R. (2018). Unsolved mysteries: How does lipid peroxidation cause ferroptosis?. PLoS Biol., 16. · DOI · Paper page
  40. Shimada, 2016, Cell-Line Selectivity Improves the Predictive Power of Pharmacogenomic Analyses and Helps Identify NADPH as Biomarker for Ferroptosis Sensitivity, Cell Chem. Biol., 23, 225, 10.1016/j.chembiol.2015.11.016 · DOI · Paper page
  41. Sato, 1999, Cloning and expression of a plasma membrane cystine/glutamate exchange transporter composed of two distinct proteins, J. Biol. Chem., 274, 11455, 10.1074/jbc.274.17.11455 · DOI · Paper page
  42. Xu, 2013, Iron and copper in mitochondrial diseases, Cell Metab., 17, 319, 10.1016/j.cmet.2013.02.004 · DOI · Paper page
  43. Beard, 2001, Iron Biology in Immune Function, Muscle Metabolism and Neuronal Functioning, J. Nutr., 131, 568S, 10.1093/jn/131.2.568S · DOI · Paper page
  44. Wang, 2017, Characterization of ferroptosis in murine models of hemochromatosis, Hepatology, 66, 449, 10.1002/hep.29117 · DOI · Paper page
  45. Lee, 2018, Ferroptosis-induced endoplasmic reticulum stress: Cross-talk between ferroptosis and apoptosis, Mol. Cancer Res., 16, 1073, 10.1158/1541-7786.MCR-18-0055 · DOI · Paper page
  46. Amri, 1994, Fatty acids as signal transducing molecules: Involvement in the differentiation of preadipose to adipose cells, J. Lipid Res., 35, 930, 10.1016/S0022-2275(20)39187-2 · DOI · Paper page
  47. De Carvalho, C.C.C.R., and Caramujo, M.J. (2018). The various roles of fatty acids. Molecules, 23. · DOI · Paper page
  48. Sellmayer, 1996, Effects of different polunsaturated fatty acids on growth-related early gene expression and cell growth, Lipids, 31, S37, 10.1007/BF02637048 · doi:10.1007/bf02637048
  49. Brash, 2001, Arachidonic acid as a bioactive molecule, J. Clin. Invest., 107, 1339, 10.1172/JCI13210 · DOI · Paper page
  50. Tang, 1996, Arachidonate lipoxygenases as essential regulators of cell survival and apoptosis, Proc. Natl. Acad. Sci. USA., 93, 5241, 10.1073/pnas.93.11.5241 · DOI · Paper page
  51. Magtanong, 2016, Emerging roles for lipids in non-apoptotic cell death, Cell Death Differ., 23, 1099, 10.1038/cdd.2016.25 · DOI · Paper page
  52. Fullerton, 2014, Immunosuppression in acutely decompensated cirrhosis is mediated by prostaglandin E2, Nat. Med., 20, 518, 10.1038/nm.3516 · DOI · Paper page
  53. McMahon, 2001, The Cap’n’Collar basic leucine zipper transcription factor Nrf2 (NF-E2 p45-related factor 2) controls both constitutive and inducible expression of intestinal detoxification and glutathione biosynthetic enzymes, Cancer Res., 61, 3299
  54. Leone, 2015, Vorinostat synergizes with EGFR inhibitors in NSCLC cells by increasing ROS via up-regulation of the major mitochondrial porin VDAC1 and modulation of the c-Myc-NRF2-KEAP1 pathway, Free Radic. Biol. Med., 89, 287, 10.1016/j.freeradbiomed.2015.07.155 · DOI
  55. Kang, 2004, Scaffolding of Keap1 to the actin cytoskeleton controls the function of Nrf2 as key regulator of cytoprotective phase 2 genes, Proc. Natl. Acad. Sci. USA, 101, 2046, 10.1073/pnas.0308347100 · DOI · Paper page
  56. Long, 2017, β-TrCP1 Is a Vacillatory Regulator of Wnt Signaling, Cell Chem. Biol., 24, 944, 10.1016/j.chembiol.2017.06.009 · DOI
  57. Takaya, 2012, Validation of the multiple sensor mechanism of the Keap1-Nrf2 system, Free Radic. Biol. Med., 53, 817, 10.1016/j.freeradbiomed.2012.06.023 · DOI · Paper page
  58. Chiu, 2014, Special issue on “Oxidative stress and mitochondrial alterations in aging and disease”, Free Radic. Res., 48, 967, 10.3109/10715762.2014.948536 · DOI
  59. Kim, 2009, 15-Deoxy-Delta12,14-prostaglandin J2 upregulates the expression of heme oxygenase-1 and subsequently matrix metalloproteinase-1 in human breast cancer cells: Possible roles of iron and ROS, Carcinogenesis, 30, 645, 10.1093/carcin/bgp012 · DOI
  60. Suzuki, 2018, An Overview of the Advantages of KEAP1-NRF2 System Activation During Inflammatory Disease Treatment, Antioxid. Redox Signal., 29, 1746, 10.1089/ars.2017.7358 · DOI
  61. Kawatani, 2011, Nrf2 and selenoproteins are essential for maintaining oxidative homeostasis in erythrocytes and protecting against hemolytic anemia, Blood, 117, 986, 10.1182/blood-2010-05-285817 · DOI
  62. Liu, 2013, Pirin is an iron-dependent redox regulator of NF-κB, Proc. Natl. Acad. Sci. USA, 110, 9722, 10.1073/pnas.1221743110 · DOI · Paper page
  63. Nakajima, 2013, Bidirectional regulation of NF-κB by reactive oxygen species: A role of unfolded protein response, Free Radic. Biol. Med., 65, 162, 10.1016/j.freeradbiomed.2013.06.020 · DOI · Paper page
  64. Kalinowski, 2012, Nitrogen monoxide (NO) storage and transport by dinitrosyl-dithiol-iron complexes: Long-lived NO that is trafficked by interacting proteins, J. Biol. Chem., 287, 6960, 10.1074/jbc.R111.329847 · DOI
  65. Richardson, 2008, The nitric oxide-iron interplay in mammalian cells: Transport and storage of dinitrosyl iron complexes, Biochim. Biophys. Acta, 1780, 638, 10.1016/j.bbagen.2007.12.009 · DOI
  66. Ding, 2000, Direct nitric oxide signal transduction via nitrosylation of iron-sulfur centers in the SoxR transcription activator, Proc. Natl. Acad. Sci. USA, 97, 5146, 10.1073/pnas.97.10.5146 · DOI · Paper page
  67. Osler, 1899, Clinical Remarks on Hypertrophic Cirrhosis of the Liver with Bronzing of the Skin: Haemochromatosis, Br. Med. J., 2, 1595, 10.1136/bmj.2.2032.1595 · doi:10.1136/bmj.2.2032.1595
  68. Anderson, 2013, Iron homeostasis in the liver, Compr. Physiol., 3, 315, 10.1002/cphy.c120016 · DOI · Paper page
  69. Niederau, 1996, Long-term survival in patients with hereditary hemochromatosis, Gastroenterology, 110, 1107, 10.1053/gast.1996.v110.pm8613000 · DOI · Paper page
  70. Fracanzani, 1995, Portal hypertension and iron depletion in patients with genetic hemochromatosis, Hepatology, 22, 1127, 10.1002/hep.1840220417 · DOI
  71. Cooksey, 2004, Oxidative stress, beta-cell apoptosis, and decreased insulin secretory capacity in mouse models of hemochromatosis, Endocrinology, 145, 5305, 10.1210/en.2004-0392 · DOI · Paper page
  72. Castro, 2002, Blood letting in high-ferritin type 2 diabetes: Effects on insulin sensitivity and beta-cell function, Diabetes, 51, 1000, 10.2337/diabetes.51.4.1000 · DOI · Paper page
  73. Valenti, 2011, Venesection for non-alcoholic fatty liver disease unresponsive to lifestyle counselling--a propensity score-adjusted observational study, QJM, 104, 141, 10.1093/qjmed/hcq170 · DOI
  74. Deugnier, 2017, Dysmetabolic iron overload syndrome (DIOS), Presse Med., 46, e306, 10.1016/j.lpm.2017.05.036 · DOI
  75. Turlin, 2001, Histologic features of the liver in insulin resistance-associated iron overload. A study of 139 patients, Am. J. Clin. Pathol., 116, 263, 10.1309/WWNE-KW2C-4KTW-PTJ5 · DOI · Paper page
  76. Marmur, J., Beshara, S., Eggertsen, G., Onelöv, L., Albiin, N., Danielsson, O., Hultcrantz, R., and Stål, P. (2018). Hepcidin levels correlate to liver iron content, but not steatohepatitis, in non-alcoholic fatty liver disease. BMC Gastroenterol., 18. · DOI
  77. Kowdley, 2012, NASH Clinical Research Network Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease, Hepatology, 55, 77, 10.1002/hep.24706 · DOI · Paper page
  78. Valenti, 2010, HFE genotype, parenchymal iron accumulation, and liver fibrosis in patients with nonalcoholic fatty liver disease, Gastroenterology, 138, 905, 10.1053/j.gastro.2009.11.013 · DOI · Paper page
  79. Fracanzani, 2011, Risk of nonalcoholic steatohepatitis and fibrosis in patients with nonalcoholic fatty liver disease and low visceral adiposity, J. Hepatol., 54, 1244, 10.1016/j.jhep.2010.09.037 · DOI
  80. Fargion, 2001, Hyperferritinemia, iron overload, and multiple metabolic alterations identify patients at risk for nonalcoholic steatohepatitis, Am. J. Gastroenterol., 96, 2448, 10.1111/j.1572-0241.2001.04052.x · doi:10.1111/j.1572-0241.2001.04052.x · Paper page
  81. Manousou, 2011, Serum ferritin is a discriminant marker for both fibrosis and inflammation in histologically proven non-alcoholic fatty liver disease patients, Liver Int., 31, 730, 10.1111/j.1478-3231.2011.02488.x · DOI · Paper page
  82. Hoki, 2015, Increased duodenal iron absorption through up-regulation of divalent metal transporter 1 from enhancement of iron regulatory protein 1 activity in patients with nonalcoholic steatohepatitis, Hepatology, 62, 751, 10.1002/hep.27774 · DOI
  83. Dongiovanni, 2011, Iron in fatty liver and in the metabolic syndrome: A promising therapeutic target, J. Hepatol., 55, 920, 10.1016/j.jhep.2011.05.008 · DOI · Paper page
  84. Beaton, M.D., Chakrabarti, S., Levstik, M., Speechley, M., Marotta, P., and Adams, P. (2013). Phase II clinical trial of phlebotomy for non-Alcoholic fatty liver disease. Aliment. Pharmacol. Ther. · DOI
  85. Schafer, 2006, Alcohol metabolism-mediated oxidative stress down-regulates hepcidin transcription and leads to increased duodenal iron transporter expression, J. Biol. Chem., 281, 22974, 10.1074/jbc.M602098200 · DOI · Paper page
  86. Klein, 2007, Iron-mediated regulation of liver hepcidin expression in rats and mice is abolished by alcohol, Hepatology, 46, 1979, 10.1002/hep.21895 · DOI · Paper page
  87. Eng, 2005, V Hepatic iron overload in alcoholic end-stage liver disease is associated with iron deposition in other organs in the absence of HFE-1 hemochromatosis, Liver Int., 25, 513, 10.1111/j.1478-3231.2005.01004.x · DOI
  88. Batista, 2012, Liver hepcidin mRNA expression is inappropriately low in alcoholic patients compared with healthy controls, Eur. J. Gastroenterol. Hepatol., 24, 1158, 10.1097/MEG.0b013e328355cfd0 · DOI
  89. Hultcrantz, 1993, Iron increases ethanol toxicity in rat liver, J. Hepatol., 17, 108, 10.1016/S0168-8278(05)80530-6 · DOI
  90. Tsukamoto, 1995, Experimental liver cirrhosis induced by alcohol and iron, J. Clin. Invest., 96, 620, 10.1172/JCI118077 · DOI · Paper page
  91. Fletcher, 2002, Excess alcohol greatly increases the prevalence of cirrhosis in hereditary hemochromatosis, Gastroenterology, 122, 281, 10.1053/gast.2002.30992 · DOI · Paper page
  92. Pietrangelo, 2003, Iron-induced oxidant stress in alcoholic liver fibrogenesis, Alcohol, 30, 121, 10.1016/S0741-8329(03)00126-5 · DOI
  93. Raynard, 2002, Risk factors of fibrosis in alcohol-induced liver disease, Hepatology, 35, 635, 10.1053/jhep.2002.31782 · DOI · Paper page
  94. Christidis, 2000, Liver iron is predictive of death in alcoholic cirrhosis: A multivariate study of 229 consecutive patients with alcoholic and/or hepatitis C virus cirrhosis: A prospective follow up study, Gut, 46, 277, 10.1136/gut.46.2.277 · DOI · Paper page
  95. Ma, L., Zou, T., Yuan, Y., Lv, J., Dong, X., Yang, G., Zhu, Y., Luo, J., Zhang, Z., and Yang, J. (2014). Duodenal ferroportin is up-regulated in patients with chronic hepatitis C. PLoS One, 9. · DOI
  96. Fujita, 2007, Hepatic oxidative DNA damage correlates with iron overload in chronic hepatitis C patients, Free Radic. Biol. Med., 42, 353, 10.1016/j.freeradbiomed.2006.11.001 · DOI
  97. Lambrecht, 2011, HALT-C Trial Group Iron levels in hepatocytes and portal tract cells predict progression and outcomes of patients with advanced chronic hepatitis C, Gastroenterology, 140, 1490, 10.1053/j.gastro.2011.01.053 · DOI
  98. Guyader, 2007, Liver iron is a surrogate marker of severe fibrosis in chronic hepatitis C, J. Hepatol., 46, 587, 10.1016/j.jhep.2006.09.021 · DOI
  99. Martin, 2013, Identification of transferrin receptor 1 as a hepatitis C virus entry factor, Proc. Natl. Acad. Sci. USA, 110, 10777, 10.1073/pnas.1301764110 · doi:10.1073/pnas.1301764110
  100. Theurl, 2004, Iron regulates hepatitis C virus translation via stimulation of expression of translation initiation factor 3, J. Infect. Dis., 190, 819, 10.1086/422261 · DOI · Paper page
  101. Li, 2016, Entry of hepatitis B and hepatitis D virus into hepatocytes: Basic insights and clinical implications, J. Hepatol., 64, S32, 10.1016/j.jhep.2016.02.011 · DOI
  102. Ryan, 2012, Pegylated interferon-α induced hypoferremia is associated with the immediate response to treatment in hepatitis C, Hepatology, 56, 492, 10.1002/hep.25666 · DOI · Paper page
  103. Ferrara, 2009, Serum ferritin as a predictor of treatment outcome in patients with chronic hepatitis C, Am. J. Gastroenterol., 104, 605
  104. Lange, 2012, Serum ferritin levels are associated with a distinct phenotype of chronic hepatitis C poorly responding to pegylated interferon-alpha and ribavirin therapy, Hepatology, 55, 1038, 10.1002/hep.24787 · DOI
  105. Andrade, 2017, Drug-induced liver injury: Recent advances in diagnosis and risk assessment, Gut, 66, 1154, 10.1136/gutjnl-2016-313369 · DOI · Paper page
  106. Lee, 2017, Acetaminophen (APAP) hepatotoxicity-Isn’t it time for APAP to go away?, J. Hepatol., 67, 1324, 10.1016/j.jhep.2017.07.005 · DOI · Paper page
  107. Du, 2016, Oxidative stress during acetaminophen hepatotoxicity: Sources, pathophysiological role and therapeutic potential, Redox Biol., 10, 148, 10.1016/j.redox.2016.10.001 · DOI · Paper page
  108. Heidari, 2016, Effect of Thiol-reducing Agents and Antioxidants on Sulfasalazine-induced Hepatic Injury in Normotermic Recirculating Isolated Perfused Rat Liver, Toxicol. Res., 32, 133, 10.5487/TR.2016.32.2.133 · DOI
  109. Ramappa, 2013, Hepatotoxicity Related to Anti-tuberculosis Drugs: Mechanisms and Management, J. Clin. Exp. Hepatol., 3, 37, 10.1016/j.jceh.2012.12.001 · DOI · Paper page
  110. Laarakkers, 2012, Acute acetaminophen intoxication leads to hepatic iron loading by decreased hepcidin synthesis, Toxicol. Sci., 129, 225, 10.1093/toxsci/kfs176 · DOI
  111. Nahon, 2008, Liver Iron, HFE Gene Mutations, and Hepatocellular Carcinoma Occurrence in Patients With Cirrhosis, Gastroenterology, 134, 102, 10.1053/j.gastro.2007.10.038 · DOI · Paper page
  112. Hellerbrand, 2003, HFE C282Y heterozygosity in hepatocellular carcinoma: Evidence for an increased prevalence, Clin. Gastroenterol. Hepatol., 1, 279, 10.1016/S1542-3565(03)00132-0 · DOI
  113. Lachaier, 2014, Sorafenib induces ferroptosis in human cancer cell lines originating from different solid tumors, Anticancer Res., 34, 6417
  114. Okuma, 2018, Survival analysis and pathological features of advanced non-small cell lung cancer with miliary pulmonary metastases in patients harboring epidermal growth factor receptor mutations, J. Cancer Res. Clin. Oncol., 144, 1601, 10.1007/s00432-018-2681-x · DOI
  115. Raja, 1994, Intestinal iron absorption studies in mouse models of iron-overload, Br. J. Haematol., 86, 156, 10.1111/j.1365-2141.1994.tb03267.x · doi:10.1111/j.1365-2141.1994.tb03267.x
  116. Fleming, R.E., Feng, Q., and Britton, R.S. (2011). Knockout Mouse Models of Iron Homeostasis. Annu. Rev. Nutr. · DOI
  117. Masaratana, 2011, Iron absorption in hepcidin1 knockout mice, Br. J. Nutr., 105, 1583, 10.1017/S0007114510005507 · DOI
  118. Lunova, 2014, Hepcidin knockout mice fed with iron-rich diet develop chronic liver injury and liver fibrosis due to lysosomal iron overload, J. Hepatol., 61, 633, 10.1016/j.jhep.2014.04.034 · DOI
  119. Kalaitzakis, 2013, Hepatic encephalopathy is related to anemia and fat-free mass depletion in liver transplant candidates with cirrhosis, Scand. J. Gastroenterol., 48, 577, 10.3109/00365521.2013.777468 · DOI
  120. Les, 2010, Quality of life in cirrhosis is related to potentially treatable factors, Eur. J. Gastroenterol. Hepatol., 22, 221, 10.1097/MEG.0b013e3283319975 · DOI · Paper page
  121. Qamar, 2009, Incidence, Prevalence, and Clinical Significance of Abnormal Hematologic Indices in Compensated Cirrhosis, Clin. Gastroenterol. Hepatol., 7, 689, 10.1016/j.cgh.2009.02.021 · DOI · Paper page
  122. Cirera, 1997, Anemia worsens hyperdynamic circulation of patients with cirrhosis and portal hypertension, Dig. Dis. Sci., 42, 1697, 10.1023/A:1018861415259 · DOI
  123. Zhang, 2019, Imidazole Ketone Erastin Induces Ferroptosis and Slows Tumor Growth in a Mouse Lymphoma Model, Cell Chem. Biol., 26, 623, 10.1016/j.chembiol.2019.01.008 · DOI · Paper page
  124. Sato, 2018, The ferroptosis inducer erastin irreversibly inhibits system xc- and synergizes with cisplatin to increase cisplatin’s cytotoxicity in cancer cells, Sci. Rep., 8, 1
  125. Bordin, 2019, Inactivation of the glutathione peroxidase GPx4 by the ferroptosis-inducing molecule RSL3 requires the adaptor protein 14-3-3ε, FEBS Lett., 594, 611
  126. Miotto, 2020, Insight into the mechanism of ferroptosis inhibition by ferrostatin-1, Redox Biol., 28, 101328, 10.1016/j.redox.2019.101328 · DOI · Paper page
  127. Liu, 2015, The 5-Lipoxygenase Inhibitor Zileuton Confers Neuroprotection against Glutamate Oxidative Damage by Inhibiting Ferroptosis, Biol. Pharm. Bull., 38, 1234, 10.1248/bpb.b15-00048 · DOI · Paper page
  128. Kajarabille, N., and Latunde-Dada, G.O. (2019). Latunde-Dada Programmed Cell-Death by Ferroptosis: Antioxidants as Mitigators. Int. J. Mol. Sci., 20. · DOI · Paper page
  129. Kagan, 2017, Oxidized Arachidonic/Adrenic Phosphatidylethanolamines Navigate Cells to Ferroptosis, Nat. Chem. Biol., 13, 81, 10.1038/nchembio.2238 · DOI · Paper page
  130. Silva, 2004, Reevaluating the role of 1,10-phenanthroline in oxidative reactions involving ferrous ions and DNA damage, Biochim. Biophys. Acta - Gen. Subj., 1675, 46, 10.1016/j.bbagen.2004.08.006 · DOI
  131. Viganor, 2016, The Antibacterial Activity of Metal Complexes Containing 1,10- phenanthroline: Potential as Alternative Therapeutics in the Era of Antibiotic Resistance, Curr. Top. Med. Chem., 17, 1280, 10.2174/1568026616666161003143333 · DOI
  132. Taher, 2016, Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with nontransfusion-dependent thalassemia syndromes, Drug Des. Devel. Ther., 10, 4073, 10.2147/DDDT.S117080 · doi:10.2147/dddt.s117080
  133. Kontoghiorghes, 2019, Prospects for the introduction of targeted antioxidant drugs for the prevention and treatment of diseases related to free radical pathology, Expert Opin. Investig. Drugs, 28, 593, 10.1080/13543784.2019.1631284 · DOI
  134. Hider, 2018, The role of deferiprone in iron chelation, N. Engl. J. Med., 379, 2140, 10.1056/NEJMra1800219 · DOI

Cited by

Metadata

Authors
Macías-Rodríguez, R. U., Inzaugarat, M. E., Ruiz-Margáin, A., Nelson, L. J., Trautwein, C., & Cubero, F. J.
Venue
International Journal of Molecular Sciences
Publisher
MDPI AG
Published
2020-02-28
Volume
21
Issue
5
Pages
1651
ISSN
1422-0067 (ISSN-L)
OpenAlex
W3009904103
Cited by
115
References
54
FWCI
9.11
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.